![Marcella Ruddy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Marcella Ruddy
Direktor/Vorstandsmitglied bei
UPSTREAM BIO, INC.
Vermögen: 2 Mio $ am 31.05.2026
Profil
Marcella Kuhlman Ruddy is currently Director at MKRuddy Consulting LLC, Independent Director at Upstream Bio, Inc. since 2023, Independent Non-Executive Director at Sionna Therapeutics, Inc. starting in 2025, and Chief Medical Officer at both Tectonic Operating Co., Inc. and Tectonic Therapeutic, Inc. since 2021.
Former roles include Non-Executive Director at Polarean Imaging Plc from 2022 to 2024, Head-Early Clinical Development at Merck & Co., Inc. from 2004 to 2014, Vice President-Clinical Development at Alnylam Pharmaceuticals, Inc. from 2015 to 2016, Vice President-Clinical Immunology at EMD Serono, Inc. in 2014, Chief Medical Officer at AVROBIO, Inc., and Head-Group Inflammation at Regeneron Pharmaceuticals, Inc. from 2016 to 2021.
Education includes undergraduate studies at Princeton University and graduate and doctorate degrees from Washington University in St. Louis.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0.36% | 04.05.2026 | 67’682 ( 0.36% ) | 2 Mio $ | 31.05.2026 |
UPSTREAM BIO, INC. -.--% | 09.06.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
| 17.06.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Marcella Ruddy
| Unternehmen | Position | Beginn |
|---|---|---|
| UPSTREAM BIO, INC. | Direktor/Vorstandsmitglied | 01.01.2023 |
| SIONNA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 08.01.2025 |
Tectonic Therapeutic, Inc.
 Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology company that transforming the discovery of novel G-protein-coupled receptors targeted therapies | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2021 |
MKRuddy Consulting LLC | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Marcella Ruddy
| Unternehmen | Position | Ende |
|---|---|---|
| POLAREAN IMAGING PLC | Direktor/Vorstandsmitglied | 24.07.2024 |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.06.2021 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.06.2016 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Corporate Officer/Principal | 01.11.2014 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01.06.2014 |
Ausbildung von Marcella Ruddy
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
84
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Regeneron Pharmaceuticals, Inc.
 Regeneron Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and commercializes medicines for diseases | Health Technology |
Washington University in St. Louis
 Washington University in St. Louis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Health Technology |
AVROBIO, Inc.
 AVROBIO, Inc. BiotechnologyHealth Technology Develops potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases in a single dose | Health Technology |
Polarean Imaging Plc
 Polarean Imaging Plc Medical SpecialtiesHealth Technology Designs, manufactures and sells noble gas polarizer devices & ancillary instruments | Health Technology |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology company that transforming the discovery of novel G-protein-coupled receptors targeted therapies | Commercial Services |
Upstream Bio, Inc.
 Upstream Bio, Inc. BiotechnologyHealth Technology Engages in developing treatments for inflammatory diseases | Health Technology |
MKRuddy Consulting LLC |
